Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2011

View Archived Issues

Eli Lilly provides update on strategy and pipeline

New full dopamine D3 receptor agonist CJ-1639 displays potent and selective activity in vivo

New synthetic aminoglycoside NB-54 shows preclinical potential as Rett syndrome therapy

First potential diagnostic marker for Churg-Strauss syndrome identified

Mitsubishi Tanabe Pharma discloses new antiplatelet agents

Lundbeck patents new phosphodiesterase 10A inhibitors

Scynexis patents new ciclosporin derivatives for hepatitis C

Pierre Fabre Medicament discloses new sucrose octasulfates of zinc

New hepatocyte growth factor receptor inhibitors presented

Boehringer Ingelheim claims new inhibitors of ribosomal protein S6 kinase alpha-3

Merck Serono's new prostanoid DP2 receptor antagonist shows potential to treat asthma

Sanofi discontinues Multaq trial in patients with permanent atrial fibrillation

Pfizer Japan and Astellas Pharma revise copromotion agreement for Caduet

GSK announces regulatory update for Votrient in advanced soft tissue sarcoma

Onconova and SymBio enter license agreement for rigosertib in Japan and Korea

Sanofi and Genzyme report encouraging phase III data on alemtuzumab in MS

Generex reports preliminary results from two trials of its mealtime insulin Generex Oral-lyn

Valeant Pharmaceuticals to acquire Sanofi's Dermik dermatology unit

Coronado Biosciences secures funds to advance CNDO-201 and CNDO-109

Qiagen increases offer price for acquisition of Cellestis

HUYA Bioscience and Liaoning (Benxi) Bio-pharmaceutical Industry Base enter strategic partnership

Qiagen enters binding agreement to acquire majority stake in Ipsogen

Amarin completes nonclinical studies for AMR-101 NDA

Alkermes discontinues development of ALKS-33 in binge eating disorder based on phase II data

FDA approves Boostrix vaccine for persons over 65 years of age

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...